A proof-of-concept clinical trial, enrolling 50 patients with advanced HCC, reported that additional ablation to anti-PD-L1 therapy increased the response rate from 10% to 24%, with the median time to progression, progression-free survival (PFS), and OS being 6.1, 5, and 16.9 months, respectively [47]. Here, CD274 is linked to hepatocellular carcinoma.